Layla A. Abushamat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Layla A. Abushamat has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
Vijay Nambi
6 shared publicationsChristie M. Ballantyne
Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX; Section of Cardiology, Baylor College of Medicine, Houston, TX
5 shared publications- Christie M. Ballantyne
Department of Medicine, Baylor College of Medicine, Houston, TX (C.M.B.).
5 shared publications - Erin Donelly Michos
Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, USA
3 shared publications - Ron Cornelis Hoogeveen
Baylor College of Medicine
3 shared publications - Vijay Nambi
Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, USA
3 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Houston Methodist DeBakey Heart & Vascular Center in Methodist DeBakey Cardiovascular Journal
- Vol. 22 (4) , 28-39
Targeting Lipoprotein(a): A New Era in Cardiovascular Disease Prevention
Lipoprotein(a), or Lp(a), is a genetically determined low-density lipoprotein-like particle that is elevated in approximately one in five individuals worldwide and represents an independent causal risk factor for atherosclerotic cardiovascular disease and calcific aortic stenosis. Elevated Lp(a) levels contribute significantly to residual cardiovascular risk despite optimal management of traditional risk factors. The pathogenicity of Lp(a) derives from its unique structure and enrichment with oxidized phospholipids, conferring proinflammatory, prothrombotic, and proatherogenic properties. Current guidelines recommend at least one-time universal screening, with elevated levels informing personalized decisions regarding lipid-lowering therapy intensification. Novel unapproved therapies, including an antisense oligonucleotide (pelacarsen), small interfering RNAs (olpasiran, lepodisiran), and an oral small molecule (muvalaplin), have demonstrated Lp(a) reductions of up to 99% and are being tested in ongoing phase 3 cardiovascular outcomes trials to determine whether pharmacologic Lp(a) lowering translates into reduced cardiovascular events. We discuss current knowledge on genetics, biology, epidemiology, and measurement of Lp(a), examine its causal association with cardiovascular disease, and discuss emerging therapeutic strategies that may usher in a new era of cardiovascular disease prevention.
- 15 September 2026
- Published by Houston Methodist DeBakey Heart & Vascular Center in Methodist DeBakey Cardiovascular Journal
- Vol. 22 (4) , 28-39
Open AccessTargeting Lipoprotein(a): A New Era in Cardiovascular Disease Prevention
Lipoprotein(a), or Lp(a), is a genetically determined low-density lipoprotein-like particle that is elevated in approximately one in five individuals worldwide and represents an independent causal risk factor for atherosclerotic cardiovascular disease and calcific aortic stenosis. Elevated Lp(a) levels contribute significantly to residual cardiovascular risk despite optimal management of traditional risk factors. The pathogenicity of Lp(a) derives from its unique structure and enrichment with oxidized phospholipids, conferring proinflammatory, prothrombotic, and proatherogenic properties. Current guidelines recommend at least one-time universal screening, with elevated levels informing personalized decisions regarding lipid-lowering therapy intensification. Novel unapproved therapies, including an antisense oligonucleotide (pelacarsen), small interfering RNAs (olpasiran, lepodisiran), and an oral small molecule (muvalaplin), have demonstrated Lp(a) reductions of up to 99% and are being tested in ongoing phase 3 cardiovascular outcomes trials to determine whether pharmacologic Lp(a) lowering translates into reduced cardiovascular events. We discuss current knowledge on genetics, biology, epidemiology, and measurement of Lp(a), examine its causal association with cardiovascular disease, and discuss emerging therapeutic strategies that may usher in a new era of cardiovascular disease prevention.
- Open Access
- 2 September 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (35)
Finding NEMO (Nuanced Effective Medical Options) for Personalized Cholesterol Management
- 2 September 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (35)
Open AccessFinding NEMO (Nuanced Effective Medical Options) for Personalized Cholesterol Management
- 8 May 2026
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (31) , 4324-4326
Eicosapentaenoic acid ethyl ester cardioprotection: beyond triglycerides
This editorial refers to ‘ Eicosapentaenoic acid ethyl ester, cardiac metabolomic and lipidomic signatures, and cardioprotection in myocardial infarction’,
- 8 May 2026
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (31) , 4324-4326
Eicosapentaenoic acid ethyl ester cardioprotection: beyond triglycerides
This editorial refers to ‘ Eicosapentaenoic acid ethyl ester, cardiac metabolomic and lipidomic signatures, and cardioprotection in myocardial infarction’,
- 7 May 2026
- Published by Elsevier in Genetics in Medicine
- Vol. 28 (7) , 102595
An integrated cardiometabolic genetic testing program in a predominantly Hispanic population within a community setting
- 7 May 2026
- Published by Elsevier in Genetics in Medicine
- Vol. 28 (7) , 102595
An integrated cardiometabolic genetic testing program in a predominantly Hispanic population within a community setting
- Open Access
- 5 March 2026
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 31
Reframing prenatal care as cardiometabolic disease prevention in women
- 5 March 2026
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 31
Open AccessReframing prenatal care as cardiometabolic disease prevention in women
- Open Access
Proteomic analysis identifies lipoprotein(a)-associated proteins linked to incident atherosclerotic cardiovascular disease events
Background: The pathways linking lipoprotein(a) (Lp[a]) to atherosclerotic cardiovascular disease (ASCVD) are unclear. This study aimed to discover Lp(a)-associated plasma proteins and estimate their associations with incident ASCVD. Methods: We analyzed 48,859 UK Biobank participants with measured Lp(a) and proteomic profiles, with replication in 9,416 individuals in the Atherosclerosis Risk in Communities (ARIC) study cohort utilizing a separate proteomic platform. Linear models assessed associations between Lp(a) and protein concentrations adjusted for age, sex, cigarette smoking, diabetes diagnosis, body mass index, systolic blood pressure, hypertension, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol, triglycerides, estimated glomerular filtration rate, statin prescription, and the first 10 components of genetic ancestry. Multiple testing correction was performed using the Benjamini-Hochberg FDR method (P < 0.05). We examined how the protein effect sizes from the primary analysis using the outcome of Lp(a) aligned with those for the outcomes of an LPA genetic risk score (GRS) and LDL-C. Cox proportional hazards models quantified hazard ratios (HRs) for protein associations with incident ASCVD. Results: Participants were a mean age of 57 years (SD 8.22), 93.9% European, and 53.8% male, with median follow-up of 8.9 years (IQR 8.3–9.7). Of 1,459 circulating proteins, 164 were significantly associated with Lp(a) after FDR correction, with enrichment for lipid degradation, metabolism, and insulin secretion. In the ARIC study, 10 proteins were replicated with consistent effect estimates. Of these replicated proteins, there were no significant associations observed with an LPA GRS. Only REG4 and VWC2 showed concordant associations with LDL-C (P < 0.001), consistent with their association with Lp(a). Five proteins exhibited concordant associations with Lp(a) and incident ASCVD (ITIH3, DLL1, REG4, VWC2, CBLN4). ITIH3 was positively associated with coronary artery disease (HR 1.13, 95% CI 1.04–1.23), peripheral artery disease (HR 1.42, 95% CI 1.19–1.69), major adverse limb events (HR 1.65, 95% CI 1.14–2.40), carotid stenosis (HR 1.45, 95% CI 1.13–1.85), and ischemic stroke (HR 1.33, 95% CI 1.13–1.55). CBLN4 uniquely showed inverse associations with Lp(a) and disease: higher levels were linked to lower risk of CAD (HR 0.88, 95% CI 0.80–0.96), PAD (HR 0.78, 95% CI 0.64–0.96), and ischemic stroke (HR 0.72, 95% CI 0.60–0.85). Conclusion: Using high-throughput proteomics, we discovered and replicated 10 proteins associated with circulating Lp(a), several of which were independent of genetically-predicted Lp(a). While Lp(a) is highly heritable, these atherogenic proteins represent a non-heritable Lp(a) axis. Clinical Perspective: What’s New?: Ten proteins associated with circulating lipoprotein(a) levels were identified and independently replicated in an external cohort, with associations independent of a genetic risk score. Five proteins (ITIH3, CBLN4, FLL1, REG4, VWC2) were concordantly associated with lipoprotein(a) and incident atherosclerotic cardiovascular disease. Clinical Implications: These proteins may represent pathways through which lipoprotein(a) drives atherosclerosis beyond traditional lipid mechanisms. Future mechanistic studies should investigate the roles of these proteins to guide the development of targeted strategies for preventing atherosclerotic cardiovascular disease.
Open AccessProteomic analysis identifies lipoprotein(a)-associated proteins linked to incident atherosclerotic cardiovascular disease events
Background: The pathways linking lipoprotein(a) (Lp[a]) to atherosclerotic cardiovascular disease (ASCVD) are unclear. This study aimed to discover Lp(a)-associated plasma proteins and estimate their associations with incident ASCVD. Methods: We analyzed 48,859 UK Biobank participants with measured Lp(a) and proteomic profiles, with replication in 9,416 individuals in the Atherosclerosis Risk in Communities (ARIC) study cohort utilizing a separate proteomic platform. Linear models assessed associations between Lp(a) and protein concentrations adjusted for age, sex, cigarette smoking, diabetes diagnosis, body mass index, systolic blood pressure, hypertension, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol, triglycerides, estimated glomerular filtration rate, statin prescription, and the first 10 components of genetic ancestry. Multiple testing correction was performed using the Benjamini-Hochberg FDR method (P < 0.05). We examined how the protein effect sizes from the primary analysis using the outcome of Lp(a) aligned with those for the outcomes of an LPA genetic risk score (GRS) and LDL-C. Cox proportional hazards models quantified hazard ratios (HRs) for protein associations with incident ASCVD. Results: Participants were a mean age of 57 years (SD 8.22), 93.9% European, and 53.8% male, with median follow-up of 8.9 years (IQR 8.3–9.7). Of 1,459 circulating proteins, 164 were significantly associated with Lp(a) after FDR correction, with enrichment for lipid degradation, metabolism, and insulin secretion. In the ARIC study, 10 proteins were replicated with consistent effect estimates. Of these replicated proteins, there were no significant associations observed with an LPA GRS. Only REG4 and VWC2 showed concordant associations with LDL-C (P < 0.001), consistent with their association with Lp(a). Five proteins exhibited concordant associations with Lp(a) and incident ASCVD (ITIH3, DLL1, REG4, VWC2, CBLN4). ITIH3 was positively associated with coronary artery disease (HR 1.13, 95% CI 1.04–1.23), peripheral artery disease (HR 1.42, 95% CI 1.19–1.69), major adverse limb events (HR 1.65, 95% CI 1.14–2.40), carotid stenosis (HR 1.45, 95% CI 1.13–1.85), and ischemic stroke (HR 1.33, 95% CI 1.13–1.55). CBLN4 uniquely showed inverse associations with Lp(a) and disease: higher levels were linked to lower risk of CAD (HR 0.88, 95% CI 0.80–0.96), PAD (HR 0.78, 95% CI 0.64–0.96), and ischemic stroke (HR 0.72, 95% CI 0.60–0.85). Conclusion: Using high-throughput proteomics, we discovered and replicated 10 proteins associated with circulating Lp(a), several of which were independent of genetically-predicted Lp(a). While Lp(a) is highly heritable, these atherogenic proteins represent a non-heritable Lp(a) axis. Clinical Perspective: What’s New?: Ten proteins associated with circulating lipoprotein(a) levels were identified and independently replicated in an external cohort, with associations independent of a genetic risk score. Five proteins (ITIH3, CBLN4, FLL1, REG4, VWC2) were concordantly associated with lipoprotein(a) and incident atherosclerotic cardiovascular disease. Clinical Implications: These proteins may represent pathways through which lipoprotein(a) drives atherosclerosis beyond traditional lipid mechanisms. Future mechanistic studies should investigate the roles of these proteins to guide the development of targeted strategies for preventing atherosclerotic cardiovascular disease.
- 26 August 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (5) , 1039-1045
PPARidgm shifts in the treatment of metabolic dysfunction–associated steatotic liver disease
- 26 August 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (5) , 1039-1045
PPARidgm shifts in the treatment of metabolic dysfunction–associated steatotic liver disease
- Open Access
- 30 July 2025
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 137 (6) , 458-464
Plain language summary about GLP-1 treatments in people with metabolic dysfunction-associated steatotic liver disease
- 30 July 2025
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 137 (6) , 458-464
Open AccessPlain language summary about GLP-1 treatments in people with metabolic dysfunction-associated steatotic liver disease
- Open Access
- 23 July 2025
- Published by Springer Nature in Nature Metabolism
- Vol. 7 (8) , 1524-1535
N-acetylaspartate from fat cells regulates postprandial body temperature
N-acetylaspartate (NAA), the brain's second most abundant metabolite, provides essential substrates for myelination through its hydrolysis1. However, the physiological roles of NAA in other tissues remain unknown. Here, we show that aspartoacylase (ASPA) expression in white adipose tissue (WAT) governs blood NAA levels for postprandial body temperature regulation. Genetic ablation of Aspa in mice resulted in systemically elevated NAA levels, and the ensuing accumulation in WAT stimulated pyrimidine production. Stable isotope tracing confirmed higher incorporation of glucose-derived carbon into pyrimidine metabolites in Aspa knockout cells. Additionally, serum NAA levels positively correlated with the abundance of the pyrimidine intermediate orotidine 5'-monophosphate, and this relationship predicted lower body mass index in humans. Using whole-body and tissue-specific knockout mouse models, we observed that fat cells provided plasma NAA and suppressed postprandial body temperature elevation. Moreover, unopposed NAA from adipocytes greatly enhanced whole-body glucose disposal exclusively in WAT. Exogenous NAA also increased plasma pyrimidines and lowered body temperature. These data place WAT-derived NAA as an endocrine regulator of postprandial body temperature and define broader roles for metabolic homeostasis.
- 23 July 2025
- Published by Springer Nature in Nature Metabolism
- Vol. 7 (8) , 1524-1535
Open AccessN-acetylaspartate from fat cells regulates postprandial body temperature
N-acetylaspartate (NAA), the brain's second most abundant metabolite, provides essential substrates for myelination through its hydrolysis1. However, the physiological roles of NAA in other tissues remain unknown. Here, we show that aspartoacylase (ASPA) expression in white adipose tissue (WAT) governs blood NAA levels for postprandial body temperature regulation. Genetic ablation of Aspa in mice resulted in systemically elevated NAA levels, and the ensuing accumulation in WAT stimulated pyrimidine production. Stable isotope tracing confirmed higher incorporation of glucose-derived carbon into pyrimidine metabolites in Aspa knockout cells. Additionally, serum NAA levels positively correlated with the abundance of the pyrimidine intermediate orotidine 5'-monophosphate, and this relationship predicted lower body mass index in humans. Using whole-body and tissue-specific knockout mouse models, we observed that fat cells provided plasma NAA and suppressed postprandial body temperature elevation. Moreover, unopposed NAA from adipocytes greatly enhanced whole-body glucose disposal exclusively in WAT. Exogenous NAA also increased plasma pyrimidines and lowered body temperature. These data place WAT-derived NAA as an endocrine regulator of postprandial body temperature and define broader roles for metabolic homeostasis.